chartexchange

Roche's Wilserdly-Everolimus Gets FDA Approval For ESR1-Mutated Advanced Breast Cancer

RTTNews | Nov 17, 2026 12:22 AM EST


(RTTNews) - Roche Holding AG (RHHBY) said the U.S. Food and Drug Administration approved Wilserdly, or giredestrant, with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Read original article